NASDAQ:RGNX - REGENXBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.78
  • Forecasted Upside: 42.83 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$34.15
▼ -0.65 (-1.87%)

This chart shows the closing price for RGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New REGENXBIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGNX

Analyst Price Target is $48.78
▲ +42.83% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for REGENXBIO in the last 3 months. The average price target is $48.78, with a high forecast of $82.00 and a low forecast of $17.00. The average price target represents a 42.83% upside from the last price of $34.15.

This chart shows the closing price for RGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in REGENXBIO. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/15/2021
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/16/2021
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/14/2021
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/11/2022WedbushReiterated RatingHold$29.00N/A
6/23/2022Berenberg BankInitiated CoverageBuy$61.00Low
6/23/2022UBS GroupLower Price TargetBuy$51.00 ➝ $47.00Low
5/24/2022Morgan StanleyLower Price TargetOverweight$51.00 ➝ $47.00High
4/11/2022Chardan CapitalReiterated RatingBuyMedium
3/29/2022Chardan CapitalLower Price Target$90.00 ➝ $76.00High
3/23/2022Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $51.00Low
3/2/2022SVB LeerinkLower Price TargetMarket Perform$29.00 ➝ $25.00Medium
2/10/2022SVB LeerinkLower Price TargetMarket Perform$35.00 ➝ $29.00High
1/28/2022SVB LeerinkLower Price TargetMarket Perform$43.00 ➝ $35.00High
12/15/2021WedbushInitiated CoverageNeutral$29.00High
11/3/2021Chardan CapitalLower Price TargetBuy$100.00 ➝ $90.00High
11/3/2021SVB LeerinkLower Price TargetMarket Perform$44.00 ➝ $43.00High
10/25/2021Roth CapitalBoost Price TargetBuy$15.00 ➝ $17.00Medium
10/12/2021SVB LeerinkReiterated RatingHoldHigh
9/14/2021Royal Bank of CanadaBoost Price TargetSector Perform$50.00 ➝ $55.00High
9/14/2021BarclaysBoost Price TargetOverweight$79.00 ➝ $82.00High
8/10/2021Chardan CapitalReiterated RatingBuy$100.00Low
7/1/2021Chardan CapitalReiterated RatingBuyLow
3/8/2021Morgan StanleyLower Price TargetOverweight$67.00 ➝ $62.00High
1/20/2021Royal Bank of CanadaBoost Price TargetNeutral ➝ Sector Perform$42.00 ➝ $50.00High
1/19/2021Morgan StanleyBoost Price TargetOverweight$51.00 ➝ $67.00Low
1/6/2021SVB LeerinkBoost Price TargetMarket Perform$34.00 ➝ $37.00N/A
1/6/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$60.00N/A
12/15/2020UBS GroupInitiated CoverageBuy$57.00Low
11/11/2020Morgan StanleyLower Price TargetOverweight$55.00 ➝ $51.00Medium
11/5/2020SVB LeerinkLower Price TargetMarket Perform$32.00 ➝ $31.00High
9/24/2020BarclaysLower Price TargetPositive ➝ Overweight$88.00 ➝ $79.00High
8/25/2020Raymond JamesReiterated RatingBuyHigh
8/14/2020Chardan CapitalReiterated RatingBuy$95.00High
8/10/2020Morgan StanleyLower Price TargetOverweight$56.00 ➝ $55.00Medium
8/4/2020Chardan CapitalReiterated RatingBuy$100.00Medium
6/25/2020Bank of AmericaInitiated CoverageBuy$60.00High
6/7/2020Chardan CapitalReiterated RatingBuyLow
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$42.00High
5/11/2020Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $56.00High
4/22/2020Chardan CapitalReiterated RatingBuy$150.00High
3/3/2020Morgan StanleyLower Price TargetOverweight$58.00 ➝ $55.00High
1/29/2020Chardan CapitalReiterated RatingBuy$150.00Low
1/17/2020Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $58.00High
12/18/2019Chardan CapitalReiterated RatingBuy$150.00Low
11/11/2019Evercore ISIReiterated RatingBuy$65.00High
10/11/2019Morgan StanleyLower Price TargetOverweight$85.00 ➝ $59.00Low
9/4/2019Chardan CapitalSet Price TargetBuy$150.00Low
8/21/2019Chardan CapitalSet Price TargetBuy$150.00Medium
8/20/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$38.00 ➝ $37.00High
8/7/2019Evercore ISISet Price TargetBuy$79.00High
7/15/2019Morgan StanleySet Price TargetBuy$84.00High
6/18/2019Chardan CapitalReiterated RatingBuy ➝ Buy$145.00 ➝ $150.00Medium
6/13/2019Raymond JamesInitiated CoverageOutperform ➝ OutperformHigh
6/5/2019Chardan CapitalReiterated RatingBuy ➝ Buy$127.50 ➝ $145.00Low
2/25/2019Evercore ISIUpgradeIn-Line ➝ Outperform$51.25High
2/5/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$94.00High
1/4/2019Chardan CapitalReiterated RatingBuy$127.50High
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$93.00 ➝ $85.00High
12/18/2018BarclaysBoost Price TargetOverweight ➝ Overweight$83.00 ➝ $88.00High
12/17/2018Chardan CapitalReiterated RatingBuy ➝ Buy$127.50High
11/27/2018SVB LeerinkInitiated CoverageUnderperform$42.00Low
11/8/2018Bank of AmericaBoost Price TargetNeutral$76.00 ➝ $84.00High
11/8/2018Raymond JamesSet Price TargetBuy$96.00High
10/29/2018Raymond JamesReiterated RatingBuyHigh
9/7/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$76.00 ➝ $96.00Low
8/13/2018BarclaysBoost Price TargetOverweight ➝ Overweight$48.00 ➝ $83.00Medium
8/8/2018Chardan CapitalLower Price TargetBuy$130.00 ➝ $127.50High
7/23/2018Bank of AmericaDowngradeBuy ➝ Neutral$64.00 ➝ $80.00Medium
7/16/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$90.00 ➝ $130.00High
7/13/2018Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $92.00Medium
7/10/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$90.00 ➝ $130.00Medium
6/25/2018Raymond JamesReiterated RatingBuy$76.00High
5/9/2018BarclaysReiterated RatingOverweight ➝ Overweight$38.00 ➝ $48.00High
5/8/2018Raymond JamesSet Price TargetBuy$45.00High
4/11/2018Raymond JamesSet Price TargetBuy$45.00Low
4/9/2018Chardan CapitalBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.00High
3/14/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$36.00 ➝ $35.00Low
2/12/2018MizuhoInitiated CoverageNeutral ➝ Neutral$28.00Low
1/5/2018Raymond JamesReiterated RatingBuyHigh
12/11/2017Chardan CapitalReiterated RatingBuyHigh
11/22/2017BarclaysInitiated CoverageOverweight$38.00N/A
11/9/2017Morgan StanleyReiterated RatingOverweight ➝ Overweight$34.00N/A
11/9/2017Chardan CapitalBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.00N/A
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$39.00N/A
10/9/2017Bank of AmericaReiterated RatingBuy$33.00 ➝ $38.00N/A
9/21/2017Bank of AmericaBoost Price TargetBuy$29.00 ➝ $33.00Low
9/5/2017Chardan CapitalReiterated RatingBuy$55.00 ➝ $75.00High
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$25.00High
8/9/2017Chardan CapitalBoost Price TargetBuy$50.00 ➝ $55.00High
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/10/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/9/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/11/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/10/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/10/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/9/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/9/2022
  • 3 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/8/2022

Current Sentiment

  • 3 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
REGENXBIO logo
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $34.15
Low: $34.11
High: $34.58

50 Day Range

MA: $26.94
Low: $19.67
High: $35.04

52 Week Range

Now: $34.15
Low: $18.69
High: $46.46

Volume

1,967 shs

Average Volume

387,524 shs

Market Capitalization

$1.48 billion

P/E Ratio

17.69

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of REGENXBIO?

The following Wall Street sell-side analysts have issued stock ratings on REGENXBIO in the last twelve months: Barclays PLC, Berenberg Bank, Chardan Capital, Morgan Stanley, Roth Capital, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TheStreet, UBS Group AG, and Wedbush.
View the latest analyst ratings for RGNX.

What is the current price target for REGENXBIO?

9 Wall Street analysts have set twelve-month price targets for REGENXBIO in the last year. Their average twelve-month price target is $48.78, suggesting a possible upside of 40.2%. Barclays PLC has the highest price target set, predicting RGNX will reach $82.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $17.00 for REGENXBIO in the next year.
View the latest price targets for RGNX.

What is the current consensus analyst rating for REGENXBIO?

REGENXBIO currently has 3 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGNX will outperform the market and that investors should add to their positions of REGENXBIO.
View the latest ratings for RGNX.

What other companies compete with REGENXBIO?

How do I contact REGENXBIO's investor relations team?

REGENXBIO's physical mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 552-8181 and its investor relations email address is [email protected] The official website for REGENXBIO is www.regenxbio.com. Learn More about contacing REGENXBIO investor relations.